31 October 2013 | News | By BioSpectrum Bureau
DSM Pharma launches new cGMP facility for biopharmaceutical contract manufacturing in Australia
Singapore: DSM Pharmaceutical, the custom manufacturing and technology business of Royal DSM, has launched its new cGMP facility for biopharmaceutical contract manufacturing in Brisbane, Australia.
The facility was built in partnership with Biopharmaceuticals Australia with cooperation from the government of Queensland and the Commonwealth of Australia.
The Brisbane facility offers cGMP mammalian cell culture contract manufacturing services from process development through to commercial manufacturing.
Mr Lukas Utiger, president and CEO, DSM Pharmaceutical Products, stated that, "With its flexible design and use of single-use technology, the facility represents the model for the future of biomanufacturing. It represents an important milestone in the development of Australia-based mammalian cell-based manufacturing of biopharmaceuticals, and extends DSM's contribution to the global biotechnology market."